Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

References

• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81. doi:10.1111/j.1478-3231.2008.01934.x
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(Suppl 1):S6–9. doi:10.1016/j.jhep.2005.09.01916352363
   PubMed Web of Science ®Google Scholar
• Peters L, Klein MB. Epidemiology of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10(5):297–302. doi:10.1097/COH.000000000000018126248117
   PubMed Web of Science ®Google Scholar
• Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808. doi:10.1016/S1473-3099(16)30197-926922272
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Peters L, Grint D, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol. 2013;59(2):213–220. doi:10.1016/j.jhep.2013.04.00523583272
   PubMed Web of Science ®Google Scholar
• Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369–379.24723077
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: a concise review and response-guided therapy proposal. World J Hepatol. 2013;5(9):496–504. doi:10.4254/wjh.v5.i9.49624073301
   PubMedGoogle Scholar
• Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49(1):22–31. doi:10.1002/hep.2259819085908
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P; AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451–459. doi:10.1056/NEJMcp04195615282352
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–450. doi:10.1056/NEJMcp04195615282351
   PubMed Web of Science ®Google Scholar
• Liu JY, Lin HH, Liu YC, et al. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clin Infect Dis. 2008;46(11):1761–1768. doi:10.1086/58799218433337
   PubMed Web of Science ®Google Scholar
• Liu CH, Sheng WH, Sun HY, et al. Peginterferon plus ribavirin for HIV-infected patients with treatment-naïve acute or chronic HCV infection in Taiwan: a prospective cohort study. Sci Rep. 2015;5:17410. doi:10.1038/srep1741026616669
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–1231. doi:10.1001/jama.2015.132825706092
   PubMed Web of Science ®Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–725. doi:10.1056/NEJMoa150315326196502
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62(12):1489–1496. doi:10.1093/cid/ciw16327025835
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713. doi:10.1056/NEJMoa150131526196665
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232–1239. doi:10.1001/jama.2015.137325706232
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and Hiv/hepatitis C virus co-infection (C-WORTHY): a randomized, open-label phase 2 trial. Lancet. 2015;385(9973):1087–1097.25467560
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–327. doi:10.1016/S2352-3018(15)00108-326423374
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus Type 1: the EXPEDITION-2 Study. Clin Infect Dis. 2018;67(7):1010–1017. doi:10.1093/cid/ciy22029566246
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Disease, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C virus. 2017 Available from: http://www.hcvguidelines.org. Accessed 5, 2018.
   Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018. doi:10.1016/j.jhep.2018.03.026
   Web of Science ®Google Scholar
• Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546–553. doi:10.1111/j.1478-3231.2009.02192.x20074094
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112. doi:10.1016/j.cgh.2009.05.03319523535
   PubMed Web of Science ®Google Scholar
• Sulkowsky MS. HCV-HIV co-infected patients: no longer a ‘special’ population? Liver Int. 2016;36(Suppl 1):43–46. doi:10.1111/liv.1302126725896
   PubMed Web of Science ®Google Scholar
• Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol Hepatol. 2015;12(4):218–230. doi:10.1038/nrgastro.2015.3625782091
   PubMed Web of Science ®Google Scholar
• Dirani G, Paesini E, Mascetra E, et al. A novel next generation sequencing assay as an alternative to currently available methods for hepatitis C virus genotyping. J Virol Methods. 2018;251:88–91. doi:10.1016/j.jviromet.2017.09.02729045810
   PubMed Web of Science ®Google Scholar
• Braun DL, Hampel B, Kouyos R, et al. High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus/hepatitis C virus–coinfected men who have sex with men. Clin Infect Dis. 2019;68(4):569–576. doi:10.1093/cid/ciy54730107485
   PubMed Web of Science ®Google Scholar
• Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12. World J Gastroenterol. 2016;22(35):8050–8059. doi:10.3748/wjg.v22.i37.831427672299
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Ghany MG, Morgan TR; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396–405. doi:10.1002/hep.2437021520194
   PubMed Web of Science ®Google Scholar